Outcomes of switching from protease inhibitor-based antiretroviral therapy to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in virologically suppressed adults with nucleos(t)ide analogue resistance– a phase IV randomised, open-label study
Authors
Chloe Bruce (ORCID: https://orcid.org/0000-0002-1099-8121)
Nicky Perry (ORCID: https://orcid.org/0000-0003-3462-130X)
Outcomes of switching from protease inhibitor-based antiretroviral therapy to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in virologically suppressed adults with nucleos(t)ide analogue resistance– a phase IV randomised, open-label study
Outcomes of switching from protease inhibitor-based antiretroviral therapy to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in virologically suppressed adults with nucleos(t)ide analogue resistance– a phase IV randomised, open-label study
Chloe Bruce, Nicky Perry, Chloe Orkin, Natalie Dailey Garnes, Stephen Bremner, Julie Fox, Collins Iwuji, Anna María Geretti, Ana Milinkovic, Frank A. Post, Laura Waters, Duncan Churchill, Ye To
article en
2 citations
Abstract
No abstract available for this paper.
Publication Tag
Virology JournalVol. 22(1)
Institutions
Brighton and Sussex Medical School (GB), University of Rome Tor Vergata (IT), University of Sussex (GB), Queen Mary University of London (GB), Royal Free London NHS Foundation Trust (GB), King's College London (GB), Guy's and St Thomas' NHS Foundation Trust (GB), Central and North West London NHS Foundation Trust (GB), Barts Health NHS Trust (GB), Chelsea and Westminster Hospital NHS Foundation Trust (GB), King's College Hospital NHS Foundation Trust (GB), Africa Health Research Institute (ZA), Mortimer Market Centre (GB), University Hospitals Sussex NHS Foundation Trust (GB)